06-07-2022 | ADA 2022 | Conference coverage | News
The ADA and KDIGO have produced a consensus statement on treating chronic kidney disease in people with diabetes.
04-04-2022 | Dapagliflozin | News
The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.
03-02-2022 | Empagliflozin | Video
Adriaan Voors discusses the EMPULSE trial of empagliflozin given just after stabilization of de novo or decompensated chronic heart failure.
06-22-2022 | SGLT2 inhibitors | News
06-21-2022 | Nephropathy | News
05-27-2022 | SGLT2 inhibitors | News
05-18-2022 | Empagliflozin | News
04-25-2022 | Dapagliflozin | News
Ian de Boer joins Amrit Lamba to discuss how these medications will influence the treatment of kidney disease in people with DKD.
04-12-2022 | SGLT2 inhibitors | News
04-05-2022 | Medications | At a glance | Article
03-01-2022 | Empagliflozin | News
02-04-2022 | Cardiovascular outcomes | News
01-10-2022 | COVID-19 | News
12-08-2021 | Empagliflozin | News
Get the latest developments in diabetes delivered straight to your inbox
Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.